Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Teva Takes Second Swing at Redo of ‘Skinny Label’ Drug Case

Oct. 8, 2021, 6:50 PM

Teva Pharmaceuticals USA Inc. is asking the full Federal Circuit to reconsider a fight over generic drug labeling that has already gone through the appeals court twice, warning “a wave of lawsuits” could threaten others bringing lower-cost medicines to market.

In August, a divided U.S. Court of Appeals for the Federal Circuit panel said language on Teva’s label for a generic version of GlaxoSmithKline PLC‘s Coreg heart drug encouraged doctors to prescribe it for federally unapproved uses. That decision came despite Teva’s use of “skinny labeling,” a practice where generic drugmakers leave a name-brand drug’s patented uses off their ...